期刊文献+

HPV L1壳蛋白与P16蛋白联合检测在宫颈癌前病变中的临床意义 被引量:8

Clinical significance of combined detection of HPV L1 capsid protein and P16 protein in cervical precancerous lesion
暂未订购
导出
摘要 目的研究HPV L1壳蛋白与P16蛋白联合运用在宫颈癌前病变诊断中的临床意义及对转归的预测价值。方法对208例TCT异常且HR-HPV阳性的患者进行宫颈活检并根据病理结果分组,同时检测其HPV L1壳蛋白和P16蛋白并根据两种抗体表达情况分为4组,并对其中随访到的155例患者进行HPV转阴分析。结果HPV L1壳蛋白和P16蛋白在不同级别宫颈组织中的表达均不同,CINⅠ组的L1壳蛋白阳性率高于其他CIN组(P<0.01),≥CINⅢ组的P16蛋白阳性率高于其他3组(P<0.01);随访病例中HPV L1壳蛋白(+)/P16蛋白(-)的转阴率高,尤其在CINⅠ患者中该组高于其他几组(P<0.05)。结论 HPV L1壳蛋白与P16蛋白联合检测可成为诊断及预测宫颈病变的一个有效指标。 Objective To evaluate the clinical significance of the combination detection of human papillomavirus(HPV)L1capsid protein and p16 protein in the diagnosis of cervical precancerous lesion and its predictive value to disease outcome.Methods 208 cases of abnormal in thinprep cytologic test and high risk(HR)-HPV positive were performed the cervical biopsy and grouped according to the histopathologic test.Meanwhile,these cases were detected the HPV L1 capsid protein and the p16 protein and then divided into 4groups according to the expression situation of these two kinds of antibody.Among them,155 followed up cases were performed the analysis of HPV negative conversion.Results The expression of L1 and P16was different among different grades of cervical tissues,the positive rate of L1 in the cervical intraepithelial neoplasia(CIN)Ⅰ group was higher than that of other CIN groups(P〈0.01)and the positive rate of P16 in the≥CINⅢ group was higher than that in the other 3groups(P〈0.01).Among the follow-up cases,the negative conversion rate in the HPV L1(+)/P16(-)was higher,especially which in the CINⅠgroup was higher than other groups(P〈0.05).Conclusion The combined detection of HPV L1 capsid protein and P16 protein can be used as an effective indicator in the diagnosis and prediction of cervical lesions.
出处 《检验医学与临床》 CAS 2015年第22期3314-3317,共4页 Laboratory Medicine and Clinic
基金 重庆市卫生和计划生育委员会医学科研资助项目(20142170) 重庆市南岸区卫生和计划生育委员会医学科研资助项目
关键词 宫颈癌前病变 HPV L1壳蛋白 P16 cervical intraepithelial neoplasia HPV L1capsid protein P16protein
  • 相关文献

参考文献14

  • 1Dhn D, Torkko K, Cshroyer R. Human papillomavirus testing and molecular markers of cervical dysplasia and careimona[J]. Cancer, 2007,111(1) : 1-14.
  • 2Bosch FX, Lorincz AT, Munoz N, et al. The causal rela- tion between human papillomavirus and cervical cancer [J]. J Clin Pathol,2002,55(4) :244-265.
  • 3Ekalasnanan T, Pientonq C, Sriamporn S, et al. Usefulness of combining testing for P16 protein and human papillo marivus(HPV) in cervical carcinoma screening[J]. Gyne- col Oncol, 2006,103 (1) : 62-66.
  • 4Seung WB, Ahwon L. Immunostaining of p16INK4a/Ki- 67 and L1 capsid protein on liquid-based cytology speci- mens obtained from ASC-H and LSIL-H cases[J]. Int J Med Sci,2013,10(12) : 1602-1607.
  • 5Stanley M. Pathology and epidemiology of HPV infection in females[J]. Gynecol Oncol, 2010, 117 (2 Suppl) :S5- S10.
  • 6Doorbar J. Molecular biology of human papillomavirus in- fection and cervical cancer[J]. Clin Sci,2006,110(5) : 525- 541.
  • 7Jones RW. The natural history of cervical and vulvar in- traepithelial neoplasia[J]. Am J Obstet Gynecol, 2010, 202(3) :12-13.
  • 8范江涛,陈心秋,张卉.表达HPV16 L1、L2和E7蛋白的非复制重组痘苗病毒诱发的抗肿瘤免疫反应[J].中国免疫学杂志,2009,25(4):317-320. 被引量:8
  • 9Lu Y, Jacobson DL, Ashworth LA, et al. Immune re- sponse to influenza vaccine in children with inflammatory bowel disease[J].Am J Gastroenterol, 2009, 104 (2) : 444-453.
  • 10Sarmadi S, Izadi-mood N, Pourlashkari M, et al. HPV L1 capsid protein expression in squamous intraepithelial le- sions of cervix uteri and its relevance to disease outcome [J].Arch Gyneeoi Obstet,2012,285(3) :779-784.

二级参考文献30

  • 1Jeon J H, Shin D M, Cho S Yet al. Immunocytochemical detection of HPV 16 E7 in cervical smear [ J ]. Exp Mol Med, 2007 ; 39 ( 5 ) : 621-628.
  • 2Bosch F X, Schiffman M, Solomon D. Future directions in epidemiologic and preventive re,arch on human papillomaviruses and cancer[J]. J Natl Cancer Inst Monogr,2003 ; (31) : 1-130.
  • 3Idotta R, Fiorino M T, Surace Pet ol. Gynecological screening for HPV infection [ J ]. Clin Exp Obstet Gynecol, 2007 ; 34 (4) : 242-243.
  • 4Matsumoto K. Human papillomavirus and cervical cancer[J]. Nippon Rinsho, 2007 ;65( 11 ) :2113-2124.
  • 5Bell M C, Mvarez R D. Chemoprevention and vacines: a review of the nonsurgical options for the treatment of cervical dysplasia[ J ]. Int J Gynecol Cancer, 2005 ; 15( 1 ) :4-12.
  • 6Feltkamp M C, Smits H L, Vierboom M Pet al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transfomaed cells [ J ]. Eur J I mmunol, 1993 ; 23 : 2242-2249.
  • 7Lin K Y, Guarnieri F G, Stavelev-o' Canrroll K F et al. Treatment of established tumor with a novel vaccine that enhance major histocompatibility class lI presentation of tumor antigen [ J ]. Cancer Res, 1996 ; 56 ( 1 ) : 21- 26.
  • 8Miyahira Y, Murata K, Rodriguez D et ol. Quantification of antigen specific CD8^+ T cell using an ELISPOT assay[J]. J lmmunol Methods, 1995; 181(1) :45-54.
  • 9Murali-Krishna K, Altman J D, Suresh M et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection [J]. Immunity, 1998;8(2) : 1771-1787.
  • 10Mundhenke C, Bauerschlag D, Fischer D et al. Malignant tumors of uterus [ J]. Ther Umsch, 2007 ; 64 (7) : 381-388.

共引文献35

同被引文献57

引证文献8

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部